Back to discover
Disease

Carcinoma of liver and intrahepatic biliary tract

Late-stage therapeutic development
Also known as carcinoma of liver and IBT, liver and intrahepatic bile duct carcinoma, liver and intrahepatic biliary tract cancer, liver and intrahepatic biliary tract carcinoma+11 more

carcinoma of liver and IBT, liver and intrahepatic bile duct carcinoma, liver and intrahepatic biliary tract cancer, liver and intrahepatic biliary tract carcinoma, primary liver carcinoma, hepatocellular carcinoma plus intrahepatic cholangiocarcinoma, cancer of liver, cancer of liver and intrahepatic biliary tract, cancer of the liver, cancer of the liver and intrahepatic biliary tract, carcinoma of liver, hepatic cancer, liver and intrahepatic bile duct cancer, liver carcinoma, liver/hepatobiliary cancer.

24
Clinical trials
12
Associated genes

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Moderate
Key developments
  • 5 clinical trials expected to report results, the earliest in Q4 2026.
Upcoming Milestones
Clinical Milestones14View all 14
Results posted 2
Results expected 5
Recently completed 5
Other updates 2
+6 more in the activity timeline below
Activity timeline14

Clinical trials

14 sponsors · 0 new · 5 completed in the last 12 months (net -1)

The current development programme across all trial phases.

Clinical programme
24
All trials
6
Active
18
Late-stage
6
Completed
Late-stage studies

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent (ARTEMIDE-Biliary01)

Phase 3 · Active, not recruiting · AstraZeneca

A Phase III, Randomized, Open-Label, Multicenter, Global Study of Volrustomig (MEDI5752) in Combination With Carboplatin Plus Pemetrexed Versus Platinum Plus Pemetrexed or Nivolumab Plus Ipilimumab in Participants With Unresectable Pleural Mesothelioma (eVOLVE-Meso)

Phase 3 · Active, not recruiting · AstraZeneca

A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma

Phase 3 · Active, not recruiting · Exelixis

A Randomized, Double-Blind Study Evaluating the Efficacy, Safety, and Immunogenicity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Treatment-Naïve Unresectable or Metastatic Melanoma

Phase 3 · Active, not recruiting · Amgen

IDE196 (Darovasertib) in Combination With Crizotinib Versus Investigator's Choice of Treatment as First-line Therapy in HLA-A2 Negative Metastatic Uveal Melanoma (DAR-UM-2)

Phase 2/3 · Active, not recruiting · IDEAYA Biosciences

Evaluating Novel Therapies and ctDNA as a Marker in Curatively-Treated Gastrointestinal Cancers With Microscopic Residual Disease

Phase 3 · Active, not recruiting · Georgetown University
Recently completed

A Randomized, Open-Label, Multicenter Phase 3 Trial of Domvanalimab, Zimberelimab, and Chemotherapy Versus Nivolumab and Chemotherapy in Participants With Previously Untreated Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma

Phase 3 · Completed · Arcus Biosciences, Inc.

TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor

Phase 3 · Completed · AVEO Pharmaceuticals, Inc.

A Randomized, Open-label, Controlled, Multicenter Phase III Clinical Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced Hepatocellular Carcinoma

Phase 3 · Completed · Innovent Biologics (Suzhou) Co. Ltd.

A Phase 3 Randomized, Double-blind, Multi-center Study of Adjuvant Nivolumab Versus Placebo in Subjects With High Risk Invasive Urothelial Carcinoma (CheckMate 274: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 274)

Phase 3 · Completed · Bristol-Myers Squibb

A Phase 3, Randomized, Open-Label Study of Nivolumab Combined With Cabozantinib Versus Sunitinib in Participants With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

Phase 3 · Completed · Bristol-Myers Squibb

Randomized Trial Sorafenib-Pravastatin Versus Sorafenib Alone for the Palliative Treatment of Child-Pugh A Hepatocellular Carcinoma

Phase 3 · Completed · Centre Hospitalier Universitaire Dijon

Associated genes

12 matches

Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.

ABI10.37ABL20.37ACVR1B0.37AFF40.37ARHGAP260.37ARHGEF120.37ARNT0.37AXIN10.37BCL100.37CBFB0.37CBLB0.37CCNB1IP10.37

Reference

Authoritative identity, definition & identifiers.

Synonyms

carcinoma of liver and IBT, liver and intrahepatic bile duct carcinoma, liver and intrahepatic biliary tract cancer, liver and intrahepatic biliary tract carcinoma, primary liver carcinoma, hepatocellular carcinoma plus intrahepatic cholangiocarcinoma, cancer of liver, cancer of liver and intrahepatic biliary tract, cancer of the liver, cancer of the liver and intrahepatic biliary tract, carcinoma of liver, hepatic cancer, liver and intrahepatic bile duct cancer, liver carcinoma, liver/hepatobiliary cancer

References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.